- Home
- SGRY vs AKRO Comparison
SGRY vs AKRO Comparison
Compare SGRY & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGRY
- AKRO
- Stock Information
- Founded
- SGRY 2004
- AKRO 2017
- Country
- SGRY United States
- AKRO United States
- Employees
- SGRY N/A
- AKRO N/A
- Industry
- SGRY Hospital/Nursing Management
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SGRY Health Care
- AKRO Health Care
- Exchange
- SGRY Nasdaq
- AKRO Nasdaq
- Market Cap
- SGRY 2.8B
- AKRO 2.8B
- IPO Year
- SGRY 2015
- AKRO 2019
- Fundamental
- Price
- SGRY $22.77
- AKRO $40.54
- Analyst Decision
- SGRY Buy
- AKRO Strong Buy
- Analyst Count
- SGRY 8
- AKRO 9
- Target Price
- SGRY $35.43
- AKRO $76.29
- AVG Volume (30 Days)
- SGRY 890.8K
- AKRO 1.1M
- Earning Date
- SGRY 05-12-2025
- AKRO 05-16-2025
- Dividend Yield
- SGRY N/A
- AKRO N/A
- EPS Growth
- SGRY N/A
- AKRO N/A
- EPS
- SGRY N/A
- AKRO N/A
- Revenue
- SGRY $3,114,300,000.00
- AKRO N/A
- Revenue This Year
- SGRY $10.88
- AKRO N/A
- Revenue Next Year
- SGRY $9.21
- AKRO N/A
- P/E Ratio
- SGRY N/A
- AKRO N/A
- Revenue Growth
- SGRY 13.52
- AKRO N/A
- 52 Week Low
- SGRY $19.50
- AKRO $17.86
- 52 Week High
- SGRY $33.97
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SGRY 53.41
- AKRO 50.63
- Support Level
- SGRY $21.30
- AKRO $41.60
- Resistance Level
- SGRY $23.29
- AKRO $46.47
- Average True Range (ATR)
- SGRY 0.54
- AKRO 2.12
- MACD
- SGRY 0.22
- AKRO 0.21
- Stochastic Oscillator
- SGRY 73.76
- AKRO 45.81
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.